[Cytomegalovirus infection in transplant recipients].
Cytomegalovirus (CMV) is the most important infectious agent in transplant recipients. The critical step in the pathogenesis of CMV infection is the reactivation of latent virus, which is affected by the immunosuppressive therapy and/or alloantigenic stimulation. The clinical effects of CMV infection include CMV disease (syndrome), an immunosuppressed state, and allograft injury. Recently, the incidence of serious CMV diseases after transplant has been decreased, probably due to the advance in the method for rapid diagnosis, the ganciclovir administration, and the effective prevention of CMV diseases. Seronegative or filtered blood products, CMV immune globulin, and prophylactic or preemptive therapy with ganciclovir appear contribute to the improvement in the prophylaxis for CMV diseases after transplant. Antigenemia-guided early treatment may be promising for the effective prevention of CMV diseases after transplant.
Gondo
H
H
First Department of Internal Medicine, Faculty of Medicine, Kyushu University.
D000212:Acyclovir / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control*; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016377:Organ Transplantation / Q000009:adverse effects*; D011292:Premedication; D005719:gamma-Globulins / Q000627:therapeutic use
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D005719:gamma-Globulins; D015774:Ganciclovir; D000212:Acyclovir